The very few ongoing clinical trials which are recruiting very rare tumors including SMARCB1-deficient cancers (NCT02834013) and recurrent/metastatic HNSCC (NCT03370276) are now under way [49,50]. The gene discussed is SMARCB1; the disease is cancer.